Century Therapeutics (IPSC) Accounts Payables (2020 - 2026)

Century Therapeutics (IPSC) has reported Accounts Payables for 7 consecutive years, with $3.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accounts Payables fell 11.84% year-over-year to $3.2 million; the TTM figure through Mar 2026 stood at $3.2 million (down 11.84% YoY), while the FY2025 annual figure was $4.8 million, up 55.22% from the prior year.
• Accounts Payables fell to $3.2 million in Q1 2026 per IPSC's latest filing, from $4.8 million in the prior quarter.
• Across five years, Accounts Payables topped out at $9.9 million in Q1 2022 and bottomed at $2.6 million in Q3 2024.
• Historically, Accounts Payables has averaged $4.2 million across 5 years, with a median of $3.5 million in 2023.
• Annual changes were most pronounced in 2022 — Accounts Payables tumbled 69.85% — and 2025, when it surged 55.22%.
• Century Therapeutics' Accounts Payables stood at $5.5 million in 2022, then tumbled by 49.74% to $2.7 million in 2023, then rose by 12.19% to $3.1 million in 2024, then soared by 55.22% to $4.8 million in 2025, then slumped by 34.0% to $3.2 million in 2026.
• Business Quant data shows IPSC's Accounts Payables at $3.2 million in Q1 2026, $4.8 million in Q4 2025, and $2.6 million in Q3 2025.